Please replace the release with the following corrected version due to multiple revisions.
The corrected release reads:
CYTOCORE INC. CONTRACTS INDUSTRY SALES VETERAN TO GROW EUROPEAN MARKET
CytoCore Inc. (OTCBB: CYOE), the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, is pleased to announce it has contracted Dr. Mauro Scimia to lead European sales and marketing services.
“Mauro is a significant addition to the CytoCore team,” said Robert McCullough Jr., CEO of CytoCore Inc. “His track record of success in cervical cytology screening and molecular testing sales combined with his focus on execution and strong management skills will be invaluable as we grow our European sales network. Dr. Scimia’s extensive knowledge of the European markets will be an integral factor in strategically positioning the products encompassing “CytoCore Solutions” including the “SoftPAP Kit” for market acceptance.”
With over 15 years of sales leadership, general management and marketing experience, Dr. Scimia has demonstrated a successful track record working with industry leaders such as Cytec – Hologic, Third Wave Technology now owned by Hologic and NeuroMedical Systems later acquired by Tripath now a division of Becton Dickinson. Dr. Scimia and his team were responsible for significantly increasing awareness and sales as products were introduced in the European markets.
“I am enthusiastic about the opportunity to join the CytoCore team,” commented Dr. Scimia. “I look forward to working with the company to build the best-in-class sales organization as we grow our market penetration in cytology. I am excited about the innovative products which encompass “CytoCore Solutions”, which should eventually detect precancerous and cancerous conditions in their early stages. They have the potential to significantly improve the quality, delivery time and cost of cytology cancer screening and diagnosis. I look forward to the launch of the “SoftPAP Kit” which includes the SoftPAP collection device and the SoftPAP preservative storage medium. The cost, comfort and medical advantages offered by the “SoftPAP Kit” for both the PAP and HPV sample collections should enhance testing compliance for cervical cancer, a leading cause of women’s death world-wide,” Scimia concluded.
“Our revised strategy incorporating both the collection device and preservative storage medium into the “SoftPAP” kit now provide our European customers with a competitive and innovative product” stated Dr. Augusto Ocana, Director of International Sales.
About CytoCore, Inc.
CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological and other cancers. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers. The CytoCore Solutions System is being developed to provide medical practitioners with highly accurate, low-cost, screening systems for cervical and other cancers that can be seamlessly integrated into existing medical models. More information is available at: www.cytocoreinc.com .
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2008. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.